2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Hepatocellular
9
Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Prostatic Neoplasms
4
Melanoma
4
Breast Neoplasms
4
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Head and Neck Neoplasms
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Pleural Effusion, Malignant
2
Mesothelioma, Malignant
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rare Malignant Neoplasm
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Nephrotic Syndrome
1
Neoplasms, Plasma Cell
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Interventions
Cyclophosphamide
101
Etoposide
60
Carboplatin
55
Vincristine
51
Filgrastim
49
Topotecan
44
Temozolomide
44
Melphalan
44
Isotretinoin
44
Doxorubicin
44
Irinotecan
42
Cisplatin
35
3-Iodobenzylguanidine
34
Peripheral Blood Stem Cell Transplantation
31
dinutuximab
30
Granulocyte Colony-Stimulating Factor
30
Radiotherapy
29
sargramostim
28
Granulocyte-Macrophage Colony-Stimulating Factor
25
Busulfan
22
Magnetic Resonance Spectroscopy
19
aldesleukin
18
Thiotepa
18
fludarabine
17
Interleukin-2
17
humanized 3F8 anti-GD2 monoclonal antibody
16
etoposide phosphate
16
naxitamab
15
Ifosfamide
15
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
Pharmaceutical Preparations
×
Clear all
NCT07334301
2026-01-12
BEACON2
University of Birmingham
Phase 1/2
Recruiting
160 enrolled